Aspen Aerogels price target lowered to $8 from $16 at Roth Capital

Roth Capital analyst Chip Moore lowered the firm’s price target on Aspen Aerogels (ASPN) to $8 from $16 and keeps a Buy rating on the shares after its Q1 results and below-consensus Q2 guide. Significant uncertainty limits near-term visibility for the company, compounded by inventory dynamics at key customer GM (GM) and broader macro considerations, though the firm also sees more limited downside as the stock’s estimates likely get washed out and a still attractive longer-term opportunity, the analyst tells investors in a research note.